Treatment Options for Steroid-Resistant Sarcoidosis

Introduction to Treatment Algorithm

The European Respiratory Society recommends methotrexate as the first-line alternative treatment for patients with steroid-resistant sarcoidosis, followed by infliximab for those who continue to have disease progression or toxicity despite methotrexate therapy 1, 2

Methotrexate is the preferred second-line agent for patients with inadequate response to steroid therapy or those experiencing steroid toxicity, with oral administration generally favored over subcutaneous for most patients 1, 3
The European Respiratory Society suggests allowing 3-6 months to assess therapeutic response to methotrexate before considering further treatment escalation 4
Folic acid supplementation may be considered to reduce methotrexate-associated side effects, though this did not reach full consensus in guidelines 3

For patients who have been treated with glucocorticoids and methotrexate with continued disease, anti-TNF therapy with infliximab is recommended by the European Respiratory Society, with infliximab being the preferred biologic agent with the strongest evidence base 2, 5
The recommended loading dose is 5 mg/kg at weeks 0, 2, and 6, followed by maintenance therapy, and combining infliximab with low-dose methotrexate may reduce the risk of autoantibody formation 3

For symptomatic pulmonary sarcoidosis with high risk of mortality or permanent disability, methotrexate followed by infliximab is recommended by the European Respiratory Society to improve/preserve forced vital capacity and quality of life 5
Inhaled corticosteroids may provide symptomatic relief for cough and asthma-like symptoms but should be discontinued if ineffective, as suggested by the European Respiratory Society 4
For patients with cutaneous sarcoidosis who have failed glucocorticoids, infliximab is recommended by the European Respiratory Society to reduce skin lesions, and hydroxychloroquine is particularly effective for skin manifestations 3, 5
For neurosarcoidosis patients who have failed glucocorticoids and methotrexate, infliximab is recommended by the European Respiratory Society, with a more aggressive treatment approach due to the high morbidity associated with neurological involvement 5

Regular monitoring for drug toxicity is essential, particularly tuberculosis screening before initiating anti-TNF therapy, as recommended by the European Respiratory Society 3
Consider Pneumocystis pneumonia prophylaxis for patients receiving multiple immunosuppressive agents, and ensure pneumococcal and influenza vaccination, as suggested by the European Respiratory Society 3

For biologic agents like infliximab, consider continuation for 2-3 years in patients who respond, and consider discontinuation of biologics after demonstration of disease stability for at least 2-3 years, as recommended by the European Respiratory Society 2, 3

Avoid prolonged corticosteroid monotherapy, as it fails to adequately address disease progression and causes significant toxicity, as warned by the European Respiratory Society 2
Allow sufficient time (3-6 months) to assess response to each new therapy before escalating treatment, as suggested by the European Respiratory Society 4
Consider lung transplantation for patients with severe disease unresponsive to therapy, worsening pulmonary function, or pulmonary hypertension, as recommended by the European Respiratory Society 3

Increasing methotrexate to 20–25 mg weekly (up from typical 15 mg) is commonly used in sarcoidosis and may improve cutaneous disease control. 6
Switching methotrexate from oral to subcutaneous administration improves bioavailability and can enhance efficacy. 7
An optimized methotrexate dose should be maintained for 3–6 months before judging treatment failure. 6

Infliximab is the first‑choice anti‑TNF biologic for cutaneous sarcoidosis that is refractory to glucocorticoids and methotrexate; multiple clinical trials support its efficacy for skin lesions, and the European Respiratory Society recommends its use in this setting. 6, 8
Adalimumab (40 mg subcutaneously weekly or every 2 weeks) is an alternative anti‑TNF agent with some evidence of benefit, though the data are less robust than for infliximab. 6, 8
Rituximab has limited data but has shown occasional effectiveness in refractory sarcoidosis; it is not the preferred biologic. 6, 8

Topical tacrolimus 0.1 % may alleviate localized skin disease, particularly erythema and itching. 9

Patients receiving ≥20 mg prednisone‑equivalent daily together with methotrexate for >6 months should be considered for Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim‑sulfamethoxazole. 6, 8
Once adequate disease control is achieved with infliximab, prednisone should be tapered to ≤10 mg daily to reduce long‑term steroid toxicity. 6, 8

If there is insufficient response after 3–6 months of optimized methotrexate, therapy should be escalated to biologics rather than continuing ineffective treatment. 6
Etanercept is ineffective for most sarcoidosis patients and should be avoided. 6, 8